Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific corporate action regarding share repurchases executed on September 5, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,291 pence per share; lowest price paid was 1,260.5 pence per share.
- Treasury Holdings (Settled): 503,996,816 shares (9.03% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,396,816 shares (9.96% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,074,317,677 shares.
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the percentage of shares held in Treasury increased to 9.96% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the 1,000,000 share repurchase based on the weighted average price between 1,260.5 and 1,291 pence.
- Confirm the impact of the 9.96% Treasury holding on earnings per share (EPS) calculations.
- Check subsequent filings to ensure the 1,000,000 shares were formally cancelled as stated.
- Validate the denominator of 5,074,317,677 shares for calculating shareholder notification thresholds under Disclosure and Transparency Rules.